SLRN Acelyrin Inc. Price Chart

The market price visualization for Acelyrin, Inc. (SLRN) on GURU.Markets, where the indicator stands at 2.26, demonstrates the price action of an R&D firm developing unique immunological treatments. The project relies on fixed testing expenses, banking on a future monopoly and high profitability from outsourced production. Low political risks are guaranteed by the humanitarian status of medicine and operations within the US and EU. Revenues are based on the supply of izakibept through insurers and dermatology centers.

Price Performance Chart: Acelyrin, Inc. (SLRN) for 02/21/2024 - 05/31/2025

Acelyrin Inc. - analytical breakdowns and key metrics (SLRN)

- stock value and consensus price forecast:

Price Chart Acelyrin, Inc.|SLRN - Analyst Median Target

- market capitalization data:

Market Value Acelyrin Inc.|SLRN - Total Company Value

- balance sheet equity data:

Net Assets per Single Share ACELYRIN|SLRN - Accounting Value of Company|Market Value to Book Value Ratio acelyrin.com|SLRN - Total Business Assets

- debt obligations and liquidity statistics:

- company profitability and valuation multiples indicators:

SLRN - Net Income|Projected Future Earnings Acelyrin, Inc.|SLRN - P/E Multiple|Projected Price to Earnings ACELYRIN|SLRN - Growth-Adjusted Payback Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Acelyrin Inc.|SLRN - Profit before interest, taxes and amortization|Net earnings per share for the last 12 months ACELYRIN|SLRN - Earnings per share for the last four quarters|Quarterly EPS earnings growth acelyrin.com|SLRN - Earnings per share increase in current year|Earnings growth forecast for next year Acelyrin, Inc.

Fundamental valuation:Acelyrin, Inc.

Acelyrin, Inc. (SLRN) development within the underserved targeted therapy segment for autoimmune diseases makes the company highly sensitive to clinical trial results. An analysis of the stock price chronology allows for the tracking of actual transaction values, reflecting the aggregate market reaction to drug development progress and the real-time valuation of capital investment potential.

Analysis of competing companies